Evaluation of corticophobia in patients with atopic dermatitis and psoriasis using the TOPICOP© score

Acta Dermatovenerol Alp Pannonica Adriat. 2023 Dec;32(4):135-139.

Abstract

Introduction: Atopic dermatitis (AD) and psoriasis (PS) are skin diseases that have a significant impact on the quality of life. The correct application of corticosteroids in topical treatment is highly effective and safe for patients. Excessive and irrational fear of these drugs based on incorrect information is increasingly observed at dermatological clinics.

Methods: To assess the extent of corticophobia, we conducted a single-center cross-sectional survey using the TOPICOP© questionnaire.

Results: The study included 57 patients (56% female) with AD and 58 patients (60% female) with PS. The combined TOPICOP© score averaged around 44, showing no significant difference between the two skin conditions. However, consistently higher scores were observed among female participants compared to males.

Conclusions: The prevalence of corticophobia was comparable to that reported in other similar studies and was higher among female patients, which replicates previous findings. Patients with AD, who were younger on average than patients with PS, often relied on friends, acquaintances, family members, and the internet as their main information sources. Providing correct and reliable information to patients is crucial for ensuring treatment adherence.

MeSH terms

  • Administration, Topical
  • Cross-Sectional Studies
  • Dermatitis, Atopic* / drug therapy
  • Female
  • Humans
  • Male
  • Psoriasis* / drug therapy
  • Quality of Life
  • Skin Diseases* / drug therapy